Skip to main content
Clinical Trials/NCT05880446
NCT05880446
Completed
Not Applicable

PROstate CAncer Radiotherapy: Its Real Impact on Bowel Symptoms & Quality of Life Today, Measured by the EORTC QLQ C30 & Specific PRT20 Module.

Jules Bordet Institute1 site in 1 country41 target enrollmentOctober 6, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Jules Bordet Institute
Enrollment
41
Locations
1
Primary Endpoint
Mean Delta of EORTC Proctitis Module (PRT20) score
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is a prospective pilot study to evaluate the mean increase of bowel symptoms after pelvic radiotherapy (RT) in prostate cancer (PCa) patient using the validated & newly translated EORTC-QLQ PRT20 module.

Detailed Description

Questionnaires (QLQ-C30 and PRT20 modules) will be held to patients at the beginning and at the end of RT (4 weeks) to evaluate the mean increase of lower GI symptoms and decrease in overall QoL after pelvic RT. For exploratory objectives, GLIM (Global Leadership Initiative on Malnutrition) criteria for malnutrition diagnosis, a 24h recall and DQI-I calculation will be assessed by the PI before the start of RT. CT sim \& dosimetry will be analyse by the PI before treatment to evaluation the body composition and the max and mean dose received by the bowel, the sigmoid and the rectum. A Polar watches will be loaned to the patient by the PI at the CT sim appointment to record patient's daily movement for two weeks (usual waiting time between CT and treatment) and recovered on the first day of treatment.

Registry
clinicaltrials.gov
Start Date
October 6, 2023
End Date
March 29, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Pauline De Bruyn

Principal Investigator

Jules Bordet Institute

Eligibility Criteria

Inclusion Criteria

  • Men with PCa which are candidate for pelvic radiotherapy (RT) with or without previous surgery, with or without concomitant hormonotherapy (HT), Performance status (PS) 0-2 (all patient able to undergo RT treatment), of all age, elderly included.

Exclusion Criteria

  • Previous RT to the pelvis
  • Diagnosed Inflammatory Bowel Disease (IBD), celiac disease
  • Severe GI symptoms before the beginning of RT (Grade \> 2 according to CTCAE grading system)
  • Obvious cognitive impairment,
  • Inability to understand French/English and no contact person able to accompany and translate.

Outcomes

Primary Outcomes

Mean Delta of EORTC Proctitis Module (PRT20) score

Time Frame: At study completion, an average of 4 months

Mean Delta between the end and the beginning of RT (4 weeks) in PRT20 score (Min 18, Max 72, higher scores mean worse outcome)

Secondary Outcomes

  • Mean Delta of EORTC Quality of Life Questionnaire (QLQ-C30) score(At study completion, an average of 4 months)

Study Sites (1)

Loading locations...

Similar Trials